ANX005-GBS-05 (Guillain-Barré syndrome)
The ANX005-GBS-05 FORWARD is a trial of the investigational drug Tanruprubart currently recruiting people with Guillain-Barré syndrome (GBS). Tanruprubart targets a key part of the immune system that is involved in GBS to temporarily shut it down and prevent nerve damage. Tanruprubart will be given as one dose that will take approximately 18 hours to administer. It is given slowly into a vein via intravenous infusion. Expected duration of participation in the study is up to 26 weeks. Participants will receive tanruprubart on the first day, and will remain in the hospital for at least 8 days to allow for close monitoring. There are about two planned study visits back at the hospital. There may be some virtual follow up appointments. Tests and assessments will include: questions about your past and current health, questions about how you are feeling, tests of muscle strength, physical exams, heart health tests, blood and urine tests. All patients will receive tanruprubart.
Enrollment Contact:
Amy Frank
(602) 406-7804
[email protected]